Life's tiniest architects pinpointed by Yale researchers
If a genome is the blueprint for life, then the chief architects are tiny slices of genetic material that orchestrate how we are assembled and function, Yale School of Medicine researchers report in the journal Developmental Cell.
The study pinpoints the molecular regulators of epigenetics – the process by which unchanging genes along our DNA are switched on and off at precisely right time and place.
"Our genome is like a landscape with lakes, mountains, and rivers, but it is not yet a community or a city full of buildings," said Haifan Lin, director of the Yale Stem Cell Center and senior author of the study. "What this system does is decide where and when to send out the masons, carpenters, and electricians to build a city or a community."
In the past 20 years, scientists have discovered that some proteins, called epigenetic factors, traverse the static genome and turn the genes on or off. The staggering number of potential combinations of active and inactive genes explains why a relatively small number of genes can carry out such a wide range of functions. But what guides these epigenetic factors to their target? The answer, the Yale team has found, is specialized RNAs called piRNAs.
In the latest study, the Yale team discovered that piRNAs guide epigenetic factors to numerous sites throughout the genome of the fruit fly Drosophila, where these switches work to turn genes on or off. The dramatic change in gene expression patterns found illustrated piRNAs key role in coordinating biological activity.
"This is the first major mechanism discovered that controls where epigenetic factors —the gene switches— are to be placed in the genome," Lin said.
Several types of cancers appeared to be triggered when the wrong kinds of piRNAs guide epigenetic factors to activate the wrong genes. Blocking the action of these piRNAs should become a new opportunity to treat cancers, Lin said.
Most read news
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
TiGenix obtains EUR 2.9 million FP7 grant to fund development of Cx611 in rheumatoid arthritis
Acute_fatty_liver_of_pregnancy
TGen and Washington University researchers discover new approach to treating endometrial cancer - Inhibitor turns 'off' receptors; stops the growth of endometrial tumors and kills cancer cells

'Relaxed' T cells critical to immune response - Researchers model how cells handle invaders, ignore imposters

Octet RH16 and RH96 | Protein analyzers | Sartorius

Organ bioprinting gets a breath of fresh air - Bioengineers clear major hurdle on path to 3D printing replacement organs

BASF strengthens its global production footprint for enzymes - BASF will invest at Novartis’ Kundl/Schaftenau Campus, in Austria
St._Jude_Children's_Research_Hospital_(Memphis,_Tennessee)
Diabetes_mellitus_and_pregnancy
